SOTIO Enrolls First Patient in Another Phase 2 Trial of Its Ovarian Cancer Immunotherapy

SOTIO Enrolls First Patient in Another Phase 2 Trial of Its Ovarian Cancer Immunotherapy
SOTIO has enrolled its first ovarian cancer patient in a Phase 2 clinical trial evaluating its immunotherapy DCVAC/OvCa. The SOV06 trial will look at the therapy's effectiveness as an add-on to standard chemotherapy in women who responded to first-line platinum-based chemo but eventually relapsed. The standard chemotherapies will be two Bristol-Myers Squibb products, Paraplatin (carboplatin) and  Taxol (paclitaxel). Positive results from other trials have also prompted Prague-based SOTIO to expand its ongoing Phase 2 SOV01 trial, which is testing DCVAC/OvCa plus chemotherapy as a first-line treatment for ovarian cancer. “SOV06 and the expansion of SOV01 represent a significant broadening of our Phase 2 program for ovarian cancer," Radek Spisek, SOTIO's chief scientific officer, said in a press release. “From ongoing clinical trials we see indications that DCVAC/OvCa in combination with first-line chemotherapy could be beneficial for patients." Expanding the program and testing DCVAC/OvCa in combination with standard chemo in patients whose cancer has returned are logical next steps, he said. The SOV06 trial will cover 30 ovarian cancer patients who have had their first relapse after chemo. SOTIO will collaborate with the Central and Eastern European Gynecological Oncology Group to conduct the trial at seven centers in the region. The trial is an "exceptional study" for the oncology g
Subscribe or to access all post and page content.